Get started
Author

Luiz Eduardo Wildemberg

Observed names: L E A Wildemberg, L. E. Wildemberg, LE Wildemberg, LUIZ EDUARDO WILDEMBERG, Luiz E Wildemberg, Luiz E. Wildemberg, Luiz Eduardo A Wildemberg, Luiz Eduardo A. Wildemberg, Luiz Eduardo Armondi Wildemberg, Luiz Eduardo Luiz Eduardo Wildemberg, Luiz Wildemberg, Wildemberg Luiz Eduardo, Wildemberg,Luiz Eduardo Armondi, wildemberg, luiz eduardo
Observed institutions: Universidade Federal do Rio de Janeiro, University of London, National Institutes of Health, Queen Mary University of London, Hospital Universitário Clementino Fraga Filho, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Max Planck Institute of Psychiatry, William Harvey Research Institute, Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione, Instituto Estadual do Cérebro Paulo Niemeyer, Secretaria de Estado de Saúde do Rio de Janeiro, Ludwig-Maximilians-Universität München, Universidade Federal de São Paulo
ORCID: 0000-0002-2692-4960
Observed ORCID: 0000-0002-2692-4960
OpenAlex ID: A5061840145
The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease
2015 · Luis G. Perez-Rivas, Marily Theodoropoulou, et al. · The Journal of Clinical Endocrinology & Metabolism · 222
PDF
Cushing's syndrome
2023 · Mônica Gadelha, Federico Gatto, et al. · The Lancet · 170
Somatostatin receptor ligands in the treatment of acromegaly
2017 · Monica R. Gadelha, Luiz Eduardo Wildemberg, et al. · Pituitary · 120
AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression
2012 · Leandro Kasuki, Leonardo Vieira Neto, et al. · Endocrine Related Cancer · 117
PDF
Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs.
2013 · L E A Wildemberg, L V Neto, et al. · PubMed · 94
Predictors of surgical outcome and early criteria of remission in acromegaly
2018 · Ximene Antunes, Nina Ventura, et al. · Endocrine · 86
The Future of Somatostatin Receptor Ligands in Acromegaly
2021 · Monica R Gadelha, Luiz Eduardo Wildemberg, et al. · The Journal of Clinical Endocrinology & Metabolism · 83
PDF
MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly
2018 · Leandro Kasuki, Luiz Eduardo Wildemberg, et al. · European Journal of Endocrinology · 81
Low Aryl Hydrocarbon Receptor-Interacting Protein Expression Is a Better Marker of Invasiveness in Somatotropinomas than Ki-67 and p53
2010 · Leandro Kasuki Jomori de Pinho, Leonardo Vieira Neto, et al. · Neuroendocrinology · 79
Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern
2013 · Leandro Kasuki, Luiz Eduardo Armondi Wildemberg, et al. · European Journal of Endocrinology · 70
Apoplexy in nonfunctioning pituitary adenomas
2018 · Luiz Eduardo Wildemberg, Andrea Glezer, et al. · Pituitary · 68
Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy
2014 · Leonardo Vieira Neto, Luiz Eduardo Wildemberg, et al. · Clinical Endocrinology · 65
ZAC1 and SSTR2 Are Downregulated in Non-Functioning Pituitary Adenomas but Not in somatotropinomas
2013 · Leonardo Vieria Neto, Luiz Eduardo Wildemberg, et al. · PLoS ONE · 57
PDF
Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands
2021 · Luiz Eduardo Wildemberg, Aline Helen da Silva Camacho, et al. · The Journal of Clinical Endocrinology & Metabolism · 56
Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features
2019 · Mari C. Vázquez-Borrego, Antonio C. Fuentes-Fayos, et al. · Cancers · 53
Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience
2023 · Mônica Gadelha, Nelma Verônica Marques, et al. · The Journal of Clinical Endocrinology & Metabolism · 36
PDF
Prolactinomas
2021 · Luiz Eduardo Wildemberg, Christhiane Fialho, et al. · La Presse Médicale · 35
PDF
Pituitary MRI Standard and Advanced Sequences: Role in the Diagnosis and Characterization of Pituitary Adenomas
2021 · Mônica R Gadelha, Monique Alvares Barbosa, et al. · The Journal of Clinical Endocrinology & Metabolism · 33
PDF
Pasireotide for the treatment of acromegaly
2016 · Luiz Eduardo Wildemberg, Mônica R. Gadelha · Expert Opinion on Pharmacotherapy · 33
Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles
2019 · Maria Caroline Alves Coelho, Marina Lipkin Vasquez, et al. · Scientific Reports · 31
Treatment escape reduces the effectiveness of cabergoline during long‐term treatment of acromegaly in monotherapy or in association with first‐generation somatostatin receptor ligands
2018 · Leandro Kasuki, Marilia Duarte Dalmolin, et al. · Clinical Endocrinology · 30
The Role of Temozolomide in the Treatment of a Patient With a Pure Silent Pituitary Somatotroph Carcinoma
2013 · Leonardo Vieira Neto, Leila Chimelli, et al. · Endocrine Practice · 27
Approach to the Patient: Differential Diagnosis of Cystic Sellar Lesions
2022 · Mônica R Gadelha, Luiz Eduardo Wildemberg, et al. · The Journal of Clinical Endocrinology & Metabolism · 26
PDF
Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT-PCR and immunohistochemistry.
2012 · L E A Wildemberg, L Vieira Neto, et al. · PubMed · 25
Association of Dengue Hemorrhagic Fever With Multiple Risk Factors for Pituitary Apoplexy
2012 · Luiz Eduardo Armondi Wildemberg, Leonardo Vieira Neto, et al. · Endocrine Practice · 25
Works count: 84
Citation count: 2,092
H-index: 25
I10-index: 41
Year
Topic
Type